Replies to post #372604 on Amarin Corp Plc (AMRN)

[couldbebetter]

Gusman, The key question remains as to who will distribute Vascepa?
AMRN itself?
A JV Partner?
A BP BO?

Is KM setting up the company for a sale? Does Denner believe he can
work with KM on a sale of the company or will a sale of the company
have to be "forced?" It should be painfully obvious that management
has really messed up a great opportunity by simply not having sold
AMRN in the past. I have no doubt that a sale of the company is
still the best solution. Denner may be capable of negotiating a
possible deal for KM, but that does not mean KM will be agreeable
to sale.

[ziploc_1]

Gusman..."Amarin will leave the US market once EU is established."

IMO Amarin will remain in the U.S. market anticipating the introduction of a patented statin-Vascepa combo product.

[IgnoranceIsBliss]

If KM does his job well, they’ll have to leave the US. There won’t be enough supply.

[lizzy241]

gusman, here's a thought to ponder. Put yourself in KM's shoes, he realizes the headwinds he has to deal with, he's one person with some people in management assisting him with the approval process. To be successful usually, a person only focuses on their goal of working through the approval process in all the countries in the EU. In the meantime, he has an incredible amount of pressure to succeed. He must depend on other people in management to take care of other tasks and rely upon their judgment to succeed in other areas of making the company run smoothly. What if these people aren't qualified to do their job while KM is in the EU, the US is a wasting asset. One fuck up and the company goes down the tubes. OR he can join forces with Denners expertise for guidance take the burden off his shoulders and share the risk with a person such as Denner et al. KM doesn't come across as a stupid person. I realize that KM answers to the board so the first move is for Denner to get a seat on the BOD maybe 2 or 3 seats. Then the company has a chance of success.